EEG Monitoring for Refractory Status Epilepticus

Launched by BARTS & THE LONDON NHS TRUST · Nov 18, 2019

Keywords

ClinConnect Summary

This clinical trial is studying the use of continuous electroencephalogram (cEEG) monitoring in patients with refractory status epilepticus (RSE), which is a serious condition where seizures do not stop despite treatment. The researchers want to find out if using cEEG in the intensive care unit (ICU) can help these patients recover faster, stay in the hospital for a shorter time, and improve their overall quality of life after discharge. The goal is to gather initial data to see how effective cEEG is compared to standard care, and to prepare for a larger study in the future.

To be eligible for this trial, participants need to be over 16 years old and must be in the ICU for treatment of status epilepticus or have been diagnosed with it during their hospital stay. They must also be experiencing seizures that continue despite receiving standard medications. Participants will be monitored with cEEG, which is a test that records brain activity, and the study will evaluate how this impacts their recovery and any complications they might face. Overall, this trial aims to improve treatment options for patients with severe seizure conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • • Patients aged \> 16 years
• • Consent obtained according to Mental Capacity Act 2005
• • Patients admitted to ICU for treatment of status epilepticus or admitted for another reason and diagnosed with SE during their admission
• * Convulsive Status epilepticus defined by either:
• • Tonic-clonic SE lasting longer than 5 minutes,
• • Focal SE with impaired consciousness lasting longer than 10 minutes
• • or Non-Convulsive SE according to Salzburg consensus criteria
• • Status epilepticus that continues despite treatment with benzodiazepine and one antiepileptic medication
• Exclusion Criteria:
• • Anoxic brain injury